Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Edesa Biotech, Inc.
Edesa Biotech, Inc. News
Edesa Biotech, Inc. Quantitative Score
About Edesa Biotech, Inc.
Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.
Edesa Biotech, Inc. Earnings & Revenue
Edesa Biotech, Inc. Financials
Table Compare
Compare EDSA metrics with: | |||
|---|---|---|---|
Earnings & Growth | EDSA | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | EDSA | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | EDSA | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | EDSA | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Edesa Biotech, Inc. Income
Edesa Biotech, Inc. Balance Sheet
Edesa Biotech, Inc. Cash Flow
Edesa Biotech, Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Neutral |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Strong Sell |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Strong Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Edesa Biotech, Inc. Valuation
Project future cash flows and get the intrinsic value per share.
Historical Market Cap
Shares Outstanding
Edesa Biotech, Inc. Executives
| Name | Role |
|---|---|
| Dr. Pardeep Nijhawan FRCPC, M.D. | Chief Executive Officer, Company Secretary & Director |
| Dr. Michael J. Brooks M.B.A., Ph.D. | President |
| Mr. Stephen L. Lemieux BA, CPA, CA, CPA, MMPA | Chief Financial Officer |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Dr. Pardeep Nijhawan FRCPC, M.D. | Chief Executive Officer, Company Secretary & Director | 1971 | 475.33K | |
| Dr. Michael J. Brooks M.B.A., Ph.D. | President | 1978 | 439.27K | |
| Mr. Stephen L. Lemieux BA, CPA, CA, CPA, MMPA | Chief Financial Officer | Male | 1977 | 402.86K |
Edesa Biotech, Inc. Insider Trades
| Date | 2 Dec |
| Name | Nijhawan Pardeep |
| Role | Chief Executive Officer |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 6420 |
| Date | 12 Nov |
| Name | Nijhawan Pardeep |
| Role | Chief Executive Officer |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 4630 |
| Date | 30 Oct |
| Name | Nijhawan Pardeep |
| Role | Chief Executive Officer |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 150 |
| Date | 30 Oct |
| Name | Nijhawan Pardeep |
| Role | Chief Executive Officer |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 326560 |
| Date | 2 Oct |
| Name | Nijhawan Pardeep |
| Role | Chief Executive Officer |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 3300 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 2 Dec | Nijhawan Pardeep | Chief Executive Officer | Acquired | A-Award | 6420 |
| 12 Nov | Nijhawan Pardeep | Chief Executive Officer | Acquired | A-Award | 4630 |
| 30 Oct | Nijhawan Pardeep | Chief Executive Officer | Acquired | A-Award | 150 |
| 30 Oct | Nijhawan Pardeep | Chief Executive Officer | Acquired | A-Award | 326560 |
| 2 Oct | Nijhawan Pardeep | Chief Executive Officer | Acquired | A-Award | 3300 |